アルファ型マンノシドーシスの世界市場レポート 2025年

アルファ型マンノシドーシス市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR17.6％で345億2,000万米ドルに成長します。予測期間の成長は、世界の人口増加と都市化、eコマースの増加、スポーツウェア需要の増加、新興経済諸国における組織小売の浸透、ソーシャルメディアの浸透の増加に起因すると考えられます。予測期間における主な動向としては、酵素療法の増加、造血幹細胞移植の採用、システナマグナ輸液の採用などが挙げられます。

精密医療に対する需要の高まりは、アルファ型マンノシドーシス市場の成長を促進すると予想されます。精密医療とは、患者の遺伝子や環境、ライフスタイルの個人差を考慮し、治療や予防戦略を最適化する個別化ヘルスケアのアプローチです。精密医療の成長には、ゲノム技術やデータ解析の進歩が寄与しており、遺伝子の変異や健康への影響をより正確に特定することが容易になっています。さらに、個別化された治療オプションに対する需要の高まりは、画一的なアプローチの限界に対する認識の高まりと相まって、オーダーメイドのヘルスケアソリューションに対する関心を高めています。プレシジョン・メディシンは、この希少疾患に関連する遺伝子変異や患者プロファイルに特化して設計された標的療法の開発を促進します。例えば、2024年2月、米国を拠点とする非営利の包括的組織である個別化医療連合（PMC）のデータから、FDAは2023年に希少疾患に対する新たな個別化治療を16件承認し、2022年のわずか6件から大幅に増加したことが明らかになった。その結果、精密医療に対する需要の高まりがアルファ型マンノシドーシス市場の成長を促進しています。

アルファ型マンノシドーシス市場の成長は、ヘルスケア支出の増加に大きく影響されています。ヘルスケア支出には、家族計画サービス、栄養プログラム、緊急医療支援、保健サービスに関連する費用が含まれます。政府のイニシアチブ、助成金、インセンティブは、アルファ型マンノシドーシスを含む希少疾患の分野における財政的支援や研究開発の促進に重要な役割を果たしています。例えば、メディケア・メディケイド・サービスセンター（CMS）が2023年6月に発表したデータによると、米国の国民医療費（NHE）は2021年に4兆3,000億米ドルに達し、国内総生産（GDP）の18.3％を占めています。このようなヘルスケア支出の増加は、ヘルスケア・イニシアチブを支援し、希少疾患の治療の進歩に貢献するというコミットメントを反映しています。その結果、ヘルスケア支出の増加がアルファ型マンノシドーシス市場を牽引すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界アルファ型マンノシドーシス PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のアルファ型マンノシドーシス市場：成長率分析
• 世界のアルファ型マンノシドーシス市場の実績：規模と成長, 2019-2024
• 世界のアルファ型マンノシドーシス市場の予測：規模と成長, 2024-2029, 2034F
• 世界アルファ型マンノシドーシス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のアルファ型マンノシドーシス市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 骨髄移植（BMT）
• 酵素補充療法（ERT）
• その他の治療法
• 世界のアルファ型マンノシドーシス市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タイプI
• タイプ II
• タイプIII
• 世界のアルファ型マンノシドーシス市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 世界のアルファ型マンノシドーシス市場骨髄移植（BMT）の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自家骨髄移植
• 同種骨髄移植
• 世界のアルファ型マンノシドーシス市場酵素補充療法（ERT）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換え酵素
• 長時間作用型酵素製剤
• 世界のアルファ型マンノシドーシス市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 対症療法
• 遺伝子治療
• 支持療法

第7章 地域別・国別分析

• 世界のアルファ型マンノシドーシス市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のアルファ型マンノシドーシス市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• アルファ型マンノシドーシス市場：競合情勢
• アルファ型マンノシドーシス市場：企業プロファイル
  • Chiesi Farmaceutici S.p.A. Overview, Products and Services, Strategy and Financial Analysis
  • Cipla Overview, Products and Services, Strategy and Financial Analysis
  • Daiichi Sankyo Company Overview, Products and Services, Strategy and Financial Analysis
  • Ultragenyx Pharmaceutical Inc Overview, Products and Services, Strategy and Financial Analysis
  • Mitsubishi Tanabe Pharma Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck
• Bristol-Myers Squibb
• Novartis AG
• Amgen
• Centogene
• Zymenex A/S
• Albumedix Ltd
• Kite Pharma
• Catalent
• Freeline Therapeutics
• Avectas
• DiNAQOR AG
• Vivet Therapeutics
• Allergan
• PsiOxus Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• アルファ型マンノシドーシス市場2029：新たな機会を提供する国
• アルファ型マンノシドーシス市場2029：新たな機会を提供するセグメント
• アルファ型マンノシドーシス市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Alpha mannosidosis is a rare genetic disorder characterized by the body's inability to effectively break down specific groups of complex sugars, leading to the accumulation of these sugars in various organs and systems, including the central nervous system. The impact of sugar buildup can vary significantly from person to person.

The primary therapeutic approaches for alpha mannosidosis include bone marrow transplant (BMT) and enzyme replacement therapy (ERT). A bone marrow transplant involves replacing dysfunctional marrow with healthy marrow to address the underlying genetic defect. Enzyme replacement therapy aims to supplement or replace a deficient enzyme in individuals lacking the enzyme or having a deficiency. The indications for alpha mannosidosis are classified into Type I, Type II, and Type III, and these therapeutic interventions are implemented across various healthcare settings, including hospitals and specialty clinics. These treatments play a crucial role in managing the symptoms and addressing the underlying genetic abnormalities associated with alpha mannosidosis.

The alpha mannosidosis market research report is one of a series of new reports from The Business Research Company that provides alpha mannosidosis market statistics, including alpha mannosidosis industry global market size, regional shares, competitors with an alpha mannosidosis market share, detailed alpha mannosidosis market segments, market trends and opportunities, and any further data you may need to thrive in the alpha mannosidosis industry. This alpha mannosidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alpha mannosidosis market size has grown rapidly in recent years. It will grow from $15.1 billion in 2024 to $18.02 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to emerging market growth, urbanization, increased demand for man-made fibers, and government initiatives for the textile industry.

The alpha mannosidosis market size is expected to see rapid growth in the next few years. It will grow to $34.52 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to global population growth and urbanization, increasing e-commerce, increasing demand for sportswear, increasing penetration of organized retail in developing economies, and increasing penetration of social media. Major trends in the forecast period include increasing the use of enzyme therapy, adopting the use of hematopoietic stem cell transplantation, and adopting the use of cisterna magna infusion.

The increasing demand for precision medicine is anticipated to drive the growth of the alpha mannosidosis market. Precision medicine is a personalized healthcare approach that considers individual differences in patients' genes, environments, and lifestyles to optimize treatment and prevention strategies. The growth of precision medicine is fueled by advancements in genomic technologies and data analytics, which facilitate more accurate identification of genetic variations and their effects on health. Furthermore, the rising demand for personalized treatment options, coupled with growing awareness of the limitations of one-size-fits-all approaches, has heightened interest in tailored healthcare solutions. Precision medicine promotes the development of targeted therapies specifically designed for the genetic mutations and patient profiles associated with this rare disorder. For example, in February 2024, data from the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit umbrella organization, revealed that the FDA approved 16 new personalized treatments for rare diseases in 2023, a significant increase from just six approvals in 2022. Consequently, the rising demand for precision medicine is propelling the growth of the alpha mannosidosis market.

The growth of the alpha mannosidosis market is significantly influenced by the increasing healthcare expenditure. Healthcare expenditure encompasses costs related to family planning services, nutrition programs, emergency medical assistance, and health services. Government initiatives, grants, and incentives play a crucial role in providing financial support and encouraging research and development in the field of rare diseases, including alpha mannosidosis. For instance, data released by the Centers for Medicare & Medicaid Services (CMS) in June 2023 indicates that the national health expenditure (NHE) in the United States reached $4.3 trillion in 2021, accounting for 18.3% of the Gross Domestic Product (GDP). This growing healthcare expenditure reflects a commitment to supporting healthcare initiatives, contributing to the advancement of treatments for rare diseases. Consequently, the increasing healthcare expenditure is expected to drive the alpha mannosidosis market.

Major companies in the alpha mannosidosis market are actively focused on developing enzyme replacement therapies to address rare alpha-mannosidosis. Enzyme replacement therapy involves supplying exogenous alpha-mannosidase, which helps reduce the accumulation of mannose-rich oligosaccharides in various tissues and organs, a characteristic feature of alpha-mannosidosis contributing to its pathological effects. A notable example is Chiesi Global Rare Diseases, a U.S.-based pharmaceutical company, which, in February 2023, launched Lamzede (velmanase alfa), the first enzyme replacement therapy authorized in the United States for treating alpha-mannosidosis. Lamzede acts similarly to the human body's alpha-mannosidase enzyme, restoring normal cellular activity in patients. The treatment involves a weekly injection of 10 mg of Lamzede.

The rise in biopharmaceutical research and development (R&D) investments is playing a significant role in driving the growth of the alpha mannosidosis market. Research and development involve the time and resources a company allocates to creating new products and improving existing ones. Enhanced understanding of the molecular underpinnings of alpha mannosidosis, along with advancements in genetic therapies, has facilitated the development of potential treatments. R&D initiatives from pharmaceutical companies and academic institutions are pivotal in fostering innovation in this area. For instance, in September 2022, the UK government reported that spending on pharmaceutical research and development reached $18.9 billion (£15.3 billion) in 2020, with a budget allocation of $49.2 billion (£39.8 billion) for R&D from 2022 to 2025. Additionally, in March 2023, Merck, a Germany-based biopharmaceutical manufacturer, announced a 3.9% increase in its R&D spending for 2022 compared to 2021. Similarly, in January 2023, Roche Holding AG, a Switzerland-based biopharmaceutical manufacturer, reported a 3.7% rise in its R&D expenditure for 2022 compared to the previous year. Consequently, the increased investments in research and development by biopharmaceutical companies are fueling the growth of the alpha mannosidosis market.

In April 2023, Italian pharmaceutical company Chiesi Farmaceutici acquired Amryt Pharma, a UK-based pharmaceutical company, for $1.25 billion. This strategic acquisition enhances Chiesi's Global Rare Diseases business division by incorporating Amryt Pharma's approved commercial products for rare diseases into its existing portfolio. Amryt Pharma is recognized for its dedication to developing and delivering innovative treatments for rare diseases.

Major companies operating in the alpha mannosidosis market include Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Merck, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd, Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma Plc, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bayer AG, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca plc, Biogen SA, Sanofi, Adcock Ingram

North America was the largest region in the alpha mannosidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the alpha mannosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The alpha mannosidosis market includes revenues earned by entities by intellectual disability, skeletal abnormalities, hearing loss, and muscle weakness. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alpha Mannosidosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alpha mannosidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alpha mannosidosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alpha mannosidosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies
• 2) By Indication: Type I, Type II, Type III
• 3) By End-User: Hospitals, Speciality Clinics
• Subsegments:
• 1) By Bone Marrow Transplant (BMT): Autologous BMT; Allogeneic BMT
• 2) By Enzyme Replacement Therapy (ERT): Recombinant Enzymes; Long-acting Enzyme Formulations
• 3) By Other Therapies: Symptomatic Treatments; Gene Therapy; Supportive Care
• Companies Mentioned: Chiesi Farmaceutici S.p.A.; Cipla; Daiichi Sankyo Company; Ultragenyx Pharmaceutical Inc; Mitsubishi Tanabe Pharma
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Alpha Mannosidosis Market Characteristics

3. Alpha Mannosidosis Market Trends And Strategies

4. Alpha Mannosidosis Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Alpha Mannosidosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Alpha Mannosidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Alpha Mannosidosis Market Growth Rate Analysis
• 5.4. Global Alpha Mannosidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Alpha Mannosidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Alpha Mannosidosis Total Addressable Market (TAM)

6. Alpha Mannosidosis Market Segmentation

• 6.1. Global Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bone Marrow Transplant (BMT)
• Enzyme Replacement Therapy (ERT)
• Other Therapies
• 6.2. Global Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type I
• Type II
• Type III
• 6.3. Global Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• 6.4. Global Alpha Mannosidosis Market, Sub-Segmentation Of Bone Marrow Transplant (BMT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous BMT
• Allogeneic BMT
• 6.5. Global Alpha Mannosidosis Market, Sub-Segmentation Of Enzyme Replacement Therapy (ERT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Enzymes
• Long-acting Enzyme Formulations
• 6.6. Global Alpha Mannosidosis Market, Sub-Segmentation Of Other Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Symptomatic Treatments
• Gene Therapy
• Supportive Care

7. Alpha Mannosidosis Market Regional And Country Analysis

• 7.1. Global Alpha Mannosidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Alpha Mannosidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Alpha Mannosidosis Market

• 8.1. Asia-Pacific Alpha Mannosidosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Alpha Mannosidosis Market

• 9.1. China Alpha Mannosidosis Market Overview
• 9.2. China Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Alpha Mannosidosis Market

• 10.1. India Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Alpha Mannosidosis Market

• 11.1. Japan Alpha Mannosidosis Market Overview
• 11.2. Japan Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Alpha Mannosidosis Market

• 12.1. Australia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Alpha Mannosidosis Market

• 13.1. Indonesia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Alpha Mannosidosis Market

• 14.1. South Korea Alpha Mannosidosis Market Overview
• 14.2. South Korea Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Alpha Mannosidosis Market

• 15.1. Western Europe Alpha Mannosidosis Market Overview
• 15.2. Western Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Alpha Mannosidosis Market

• 16.1. UK Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Alpha Mannosidosis Market

• 17.1. Germany Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Alpha Mannosidosis Market

• 18.1. France Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Alpha Mannosidosis Market

• 19.1. Italy Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Alpha Mannosidosis Market

• 20.1. Spain Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Alpha Mannosidosis Market

• 21.1. Eastern Europe Alpha Mannosidosis Market Overview
• 21.2. Eastern Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Alpha Mannosidosis Market

• 22.1. Russia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Alpha Mannosidosis Market

• 23.1. North America Alpha Mannosidosis Market Overview
• 23.2. North America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Alpha Mannosidosis Market

• 24.1. USA Alpha Mannosidosis Market Overview
• 24.2. USA Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Alpha Mannosidosis Market

• 25.1. Canada Alpha Mannosidosis Market Overview
• 25.2. Canada Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Alpha Mannosidosis Market

• 26.1. South America Alpha Mannosidosis Market Overview
• 26.2. South America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Alpha Mannosidosis Market

• 27.1. Brazil Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Alpha Mannosidosis Market

• 28.1. Middle East Alpha Mannosidosis Market Overview
• 28.2. Middle East Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Alpha Mannosidosis Market

• 29.1. Africa Alpha Mannosidosis Market Overview
• 29.2. Africa Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Alpha Mannosidosis Market Competitive Landscape And Company Profiles

• 30.1. Alpha Mannosidosis Market Competitive Landscape
• 30.2. Alpha Mannosidosis Market Company Profiles
  • 30.2.1. Chiesi Farmaceutici S.p.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Cipla Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Daiichi Sankyo Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Ultragenyx Pharmaceutical Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Mitsubishi Tanabe Pharma Overview, Products and Services, Strategy and Financial Analysis

31. Alpha Mannosidosis Market Other Major And Innovative Companies

• 31.1. Merck
• 31.2. Bristol-Myers Squibb
• 31.3. Novartis AG
• 31.4. Amgen
• 31.5. Centogene
• 31.6. Zymenex A/S
• 31.7. Albumedix Ltd
• 31.8. Kite Pharma
• 31.9. Catalent
• 31.10. Freeline Therapeutics
• 31.11. Avectas
• 31.12. DiNAQOR AG
• 31.13. Vivet Therapeutics
• 31.14. Allergan
• 31.15. PsiOxus Therapeutics

32. Global Alpha Mannosidosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Alpha Mannosidosis Market

34. Recent Developments In The Alpha Mannosidosis Market

35. Alpha Mannosidosis Market High Potential Countries, Segments and Strategies

• 35.1 Alpha Mannosidosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Alpha Mannosidosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Alpha Mannosidosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer